Temasek, Singapore's state-owned investment firm, sees the biggest market risk as a potential reversal in the artificial intelligence (AI) trade, which currently supports U.S. stock highs despite rising Treasury yields. Factors like tighter regulations due to safety concerns or poor returns on AI investments could trigger this reversal. However, Temasek remains optimistic about AI's long-term prospects and is increasing its investments, aiming to shift more exposure to publicly traded AI assets for greater flexibility as the sector evolves.
Singapore's Temasek highlights market risks around AI trades, offering context with Pluang's technology sector data. For readers following technology stocks, here is Pluang's market snapshot as of Oct 07, 2026 10:41 WIB: out of 150 priced US tech stocks, 68 rose and 80 fell. Notable movers include Expensify Inc (EXFY) down 5.96% at USD 2.21 with 100% buy orders, KLA Corp. (KLAC) down 5.46% at USD 195.56 with nearly balanced buy/sell orders, and Zscaler Inc (ZS) up 5.30% at USD 212.49 with 86% sell orders.
The Reserve Bank of India raised its key policy rate by 25 basis points to 5.5%, marking the first increase since 2023. This move aims to curb rising inflation, which has been increasing for 10 consecutive months and currently stands above the RBI's ...
On October 6, U.S. spot Bitcoin ETFs attracted $118.8 million in net inflows, driven mainly by IBIT which contributed $122 million, making it the largest positive inflow among Bitcoin ETFs. In contrast, Ethereum ETFs experienced $201.9 million in net...
U.S. spot Bitcoin exchange-traded funds (ETFs) recorded net inflows of $118.8 million on October 6, reversing a prior session's outflow. Over five days, total inflows reached $172.9 million, with BlackRock's iShares Bitcoin Trust leading at $122 mill...
Abstract, an Ethereum layer-2 blockchain focused on consumer applications, will shut down on December 15 after its parent company Igloo lost tens of millions of dollars funding it. Despite processing over 325 million transactions and hosting $6 billi...
Palindrome Pharma, a new Canadian pharmaceutical company, has launched with a focus on biosimilar medicines to improve access to biologic therapies and support a sustainable healthcare system. The company aims to build a diverse portfolio through par...
